Danielle Brill
Stock Analyst at Truist Securities
(3.94)
# 624
Out of 5,118 analysts
93
Total ratings
48.15%
Success rate
12.65%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PVLA Palvella Therapeutics | Maintains: Buy | $105 → $190 | $101.15 | +87.85% | 4 | Dec 16, 2025 | |
| IRON Disc Medicine | Maintains: Buy | $86 → $114 | $78.29 | +45.61% | 7 | Nov 10, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Buy | $165 → $172 | $143.64 | +19.74% | 7 | Oct 30, 2025 | |
| BBIO BridgeBio Pharma | Reiterates: Buy | $66 → $80 | $75.61 | +5.81% | 2 | Oct 30, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $459 → $535 | $398.82 | +34.15% | 2 | Oct 17, 2025 | |
| IMVT Immunovant | Initiates: Hold | $16 | $25.61 | -37.52% | 5 | Oct 14, 2025 | |
| UPB Upstream Bio | Initiates: Buy | $47 | $28.83 | +63.02% | 1 | Oct 14, 2025 | |
| DNTH Dianthus Therapeutics | Initiates: Buy | $56 | $41.57 | +34.71% | 1 | Oct 14, 2025 | |
| VRTX Vertex Pharmaceuticals | Initiates: Market Perform | n/a | $459.78 | - | 3 | Sep 3, 2025 | |
| HRMY Harmony Biosciences Holdings | Initiates: Buy | $48 | $37.91 | +26.62% | 8 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $64 | $20.77 | +208.14% | 2 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $24.79 | +21.02% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $22.94 | +4.62% | 1 | Jul 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Strong Buy | $20 → $52 | $24.56 | +111.73% | 6 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $16.58 | - | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $79 | $60.04 | +31.58% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $18 | $14.30 | +25.87% | 1 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $150 | $21.82 | +587.44% | 3 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $176.83 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $837.45 | -27.76% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $27.26 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $44.33 | +12.79% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $27.16 | +87.78% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $180 → $100 | $11.08 | +802.53% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $77.64 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $8.78 | - | 5 | Jun 27, 2023 |
Palvella Therapeutics
Dec 16, 2025
Maintains: Buy
Price Target: $105 → $190
Current: $101.15
Upside: +87.85%
Disc Medicine
Nov 10, 2025
Maintains: Buy
Price Target: $86 → $114
Current: $78.29
Upside: +45.61%
Neurocrine Biosciences
Oct 30, 2025
Reiterates: Buy
Price Target: $165 → $172
Current: $143.64
Upside: +19.74%
BridgeBio Pharma
Oct 30, 2025
Reiterates: Buy
Price Target: $66 → $80
Current: $75.61
Upside: +5.81%
Alnylam Pharmaceuticals
Oct 17, 2025
Maintains: Buy
Price Target: $459 → $535
Current: $398.82
Upside: +34.15%
Immunovant
Oct 14, 2025
Initiates: Hold
Price Target: $16
Current: $25.61
Upside: -37.52%
Upstream Bio
Oct 14, 2025
Initiates: Buy
Price Target: $47
Current: $28.83
Upside: +63.02%
Dianthus Therapeutics
Oct 14, 2025
Initiates: Buy
Price Target: $56
Current: $41.57
Upside: +34.71%
Vertex Pharmaceuticals
Sep 3, 2025
Initiates: Market Perform
Price Target: n/a
Current: $459.78
Upside: -
Harmony Biosciences Holdings
Jul 21, 2025
Initiates: Buy
Price Target: $48
Current: $37.91
Upside: +26.62%
Jul 21, 2025
Initiates: Buy
Price Target: $64
Current: $20.77
Upside: +208.14%
Jul 21, 2025
Initiates: Buy
Price Target: $30
Current: $24.79
Upside: +21.02%
Jul 21, 2025
Initiates: Buy
Price Target: $24
Current: $22.94
Upside: +4.62%
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $24.56
Upside: +111.73%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $16.58
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $60.04
Upside: +31.58%
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $14.30
Upside: +25.87%
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $21.82
Upside: +587.44%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $176.83
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $837.45
Upside: -27.76%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $27.26
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $44.33
Upside: +12.79%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $27.16
Upside: +87.78%
Nov 14, 2023
Maintains: Outperform
Price Target: $180 → $100
Current: $11.08
Upside: +802.53%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $77.64
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $8.78
Upside: -